Growth hormone axis
IGF-1 LR3
- 1 mg
Custom strengths on request
Not FDA-approved. Not on FDA's 503A category lists (May 14, 2026). Source, May 14, 2026
At a glance
These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.
No established human dose
No peer-reviewed human studies of IGF-1 LR3 were found, and a 2026 narrative review places it in its lowest evidence tier (no human studies). The located LR3 literature is cell-line, animal or analytical work: diabetic rats (LR3 2.5-3x more potent than IGF-I in restoring growth, PMID 7683875), tumour-bearing rats (tumour growth increased, especially by LR3, PMID 8053901), neonatal pigs (LR3 infusion lowered measured plasma IGF-I, PMID 12067429), mouse and fetal sheep work, and anti-doping analytics (PMID 33587816). Human dose figures come only from forum, vendor and clinic-education statements, which the sources themselves describe as not coming from any clinical trial. There are no human study doses. The human safety signals below come from native rhIGF-I or mecasermin. They are context only and never a basis for dosing.
Get a quote
Custom strengths on request. Prices are quoted per clinic.